1. Home
  2. FOLD vs TGNA Comparison

FOLD vs TGNA Comparison

Compare FOLD & TGNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FOLD
  • TGNA
  • Stock Information
  • Founded
  • FOLD 2002
  • TGNA 1906
  • Country
  • FOLD United States
  • TGNA United States
  • Employees
  • FOLD N/A
  • TGNA N/A
  • Industry
  • FOLD Biotechnology: Pharmaceutical Preparations
  • TGNA Broadcasting
  • Sector
  • FOLD Health Care
  • TGNA Industrials
  • Exchange
  • FOLD Nasdaq
  • TGNA Nasdaq
  • Market Cap
  • FOLD 2.8B
  • TGNA 2.9B
  • IPO Year
  • FOLD 2007
  • TGNA N/A
  • Fundamental
  • Price
  • FOLD $9.58
  • TGNA $17.96
  • Analyst Decision
  • FOLD Strong Buy
  • TGNA Buy
  • Analyst Count
  • FOLD 8
  • TGNA 3
  • Target Price
  • FOLD $17.00
  • TGNA $21.67
  • AVG Volume (30 Days)
  • FOLD 2.1M
  • TGNA 1.4M
  • Earning Date
  • FOLD 02-26-2025
  • TGNA 02-27-2025
  • Dividend Yield
  • FOLD N/A
  • TGNA 2.75%
  • EPS Growth
  • FOLD N/A
  • TGNA N/A
  • EPS
  • FOLD N/A
  • TGNA 2.81
  • Revenue
  • FOLD $493,671,000.00
  • TGNA $2,957,296,000.00
  • Revenue This Year
  • FOLD $34.33
  • TGNA $8.66
  • Revenue Next Year
  • FOLD $21.70
  • TGNA N/A
  • P/E Ratio
  • FOLD N/A
  • TGNA $6.35
  • Revenue Growth
  • FOLD 32.58
  • TGNA N/A
  • 52 Week Low
  • FOLD $8.79
  • TGNA $12.35
  • 52 Week High
  • FOLD $14.03
  • TGNA $19.62
  • Technical
  • Relative Strength Index (RSI)
  • FOLD 50.06
  • TGNA 40.39
  • Support Level
  • FOLD $8.79
  • TGNA $17.73
  • Resistance Level
  • FOLD $9.63
  • TGNA $18.70
  • Average True Range (ATR)
  • FOLD 0.29
  • TGNA 0.38
  • MACD
  • FOLD 0.05
  • TGNA -0.08
  • Stochastic Oscillator
  • FOLD 90.48
  • TGNA 8.40

About FOLD Amicus Therapeutics Inc.

Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.

About TGNA TEGNA Inc

Tegna Inc is a media company with a portfolio of broadcast stations and digital sites. The firm has television stations and radio stations in approximately U.S. markets. The company owns multicast networks of True Crime Network, Twist, and Quest. Each television station also has a robust digital presence across online, mobile, connected television, and social platforms, reaching consumers on all devices and platforms used to consume news content. It generates key revenue from advertising and marketing services, subscriptions, political advertising, and other services.

Share on Social Networks: